Biological diagnosis of resistance to erlotinib in a malignant pleural effusion;Diagnostic biologique de résistance à l'erlotinib sur une pleurésie

Revue des Maladies Respiratoires

Volumn 30, Issue 7, 2013, Pages 572-575

  Rieux, C ^a,b   Boisdron Celle, M ^b   Morel, A ^b   Fey, L ^b   Urban, T ^a,b   Hureaux, J ^a,b  

^a LUNAM Universite   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Drug resistance neoplasm; Epidermal growth factor receptor (EGFR); Malignant pleural effusion; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ASPIRATION; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALIGNANT PLEURA EFFUSION; TUMOR RESISTANCE;

CANCER BRONCHIQUE NON À PETITES CELLULES; DRUG RESISTANCE NEOPLASM; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); INHIBITEUR TYROSINE KINASE; MALIGNANT PLEURAL EFFUSION; NON-SMALL CELL LUNG CANCER; PLEURÉSIE MÉTASTATIQUE; RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE (EGFR); RÉSISTANCE AUX ANTICANCÉREUX; TYROSINE KINASE INHIBITOR;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84892616360     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2013.02.010     Document Type: Article

References (12)

1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80.
2. Institut national du cancer. Programme INCa pour la détection des biomarqueurs émergents dans le cancer du poumon, le cancer colorectal et le mélanome: une nouvelle approche pour un accès rapide aux thérapies ciblées ; 2010 [ http://www.e-cancer.fr/component/ docman/doc download/5119-programme-inca-biomarqueurs-emergents].
3. Institut national du cancer. Bonnes pratiques pour la recherche à visée théranostique de mutations somatiques dans les tumeurs solides; 2010 [ http://www.e-cancer.fr/component/docman/doc download/5774- recherche-a-visee-theranostique].
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
5. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
6. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
7. Gharizadeh B, Nordstrom T, Ahmadian A, et al. Long-read pyrosequencing using pure 2'-deoxyadenosine-5'-O'-(1-thiotriphosphate) Sp-isomer. Anal Biochem 2002;301:82-90. (Pubitemid 34113681)
8. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357-60.
9. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17:1616-22.
10. Shih JY, Gow CH, Yang PC. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med 2005;353:207-8.
11. Oh JE, An CH, Yoo NJ, et al. Detection of low-level EGFR T790M mutation in lung cancer tissues. APMIS 2011;119:403-11.
12. Jian G, Songwen Z, Ling Z, et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:1341-7.